Eli Lilly (LLY) said Tuesday it will soon ask global regulators to approve its weight-loss pill, orforglipron, following a third successful Phase 3 study in patients with type 2 diabetes and obesity.… [+3050 chars]Read More
Lilly Scores Another Obesity Win Viking Novo Stocks Slump Investors Business Daily
